Patents by Inventor Kathryn Rene Bracken

Kathryn Rene Bracken has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8044199
    Abstract: Novel N-formyl hydroxylamine compounds of formula I: wherein R1 is hydrogen, alkyl, heteroaryl, heterocycloalkyl, aryl, heteroaryl or cycloalkyl; R3 is hydrogen, halogen or alkoxy; R4 is pyridazinyl; n is 0 to 3; and wherein one or more of the ring nitrogen heteroatoms of said pyridazinyl is optionally oxidized and their derivatives are disclosed. These N-formyl hydroxylamine compounds inhibit peptidyl deformylase (PDF), an enzyme present in prokaryotes. The compounds are useful as antimicrobials and antibiotics. The compounds of the invention display selective inhibition of peptidyl deformylase versus other metalloproteinases such as MMPs. Methods of preparation and use of the compounds are also disclosed.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: October 25, 2011
    Assignee: Vicuron Holdings LLC
    Inventors: Kathryn Rene Bracken, Simon Bushell, Karl Dean, Charles Francavilla, Rakesh K. Jain, Kwangho Lee, Mohindra Seepersaud, Lei Shu, Arathi Sundaram, Zhengyu Yuan
  • Publication number: 20100063278
    Abstract: Novel N-formyl hydroxylamine compounds and their derivatives are discloses. These N-formyl hydroxylamine compounds inhibit peptidyl deformylase (PDF), an enzyme present in prokaryotes. The compounds are useful as antimicrobials and antibiotics. The compounds of the invention display selective inhibition of peptidyl deformylase versus other metalloproteinases such as MMPs. Methods of preparation and use of the compounds are also disclosed.
    Type: Application
    Filed: June 2, 2009
    Publication date: March 11, 2010
    Applicants: Novartis AG, Vicuron Pharmaceuticals, Inc.
    Inventors: Kathryn Rene Bracken, Simon Bushell, Karl Dean, Charles Francavilla, Rakesh K. Jain, Kwangho Lee, Mohindra Seepersaud, Lei Shu, Arathi Sundaram, Zhengyu Yuan
  • Patent number: 7615635
    Abstract: Novel N-formyl hydroxylamine compounds and their derivatives are disclosed. These N-formyl hydroxylamine compounds inhibit peptidyl deformylase (PDF), an enzyme present in prokaryotes. The compounds are useful as antimicrobials and antibiotics. The compounds of the invention display selective inhibition of peptidyl deformylase versus other metalloproteinases such as MMPs. Methods of preparation and use of the compounds are also disclosed.
    Type: Grant
    Filed: May 22, 2006
    Date of Patent: November 10, 2009
    Assignees: Novartis AG, Vicuron Pharmaceuticals, Inc.
    Inventors: Kathryn Rene Bracken, Simon Bushell, Karl Dean, Charles Francavilla, Rakesh K. Jain, Kwangho Lee, Mohindra Seepersaud, Lei Shu, Arathi Sundaram, Zhengyu Yuan
  • Publication number: 20080161558
    Abstract: Novel N-formyl hydroxylamine compounds and their derivatives are disclosed. These N-formyl hydroxylamine compounds inhibit peptidyl deformylase (PDF), an enzyme present in prokaryotes. The compounds are useful as antimicrobials and antibiotics. The compounds of the invention display selective inhibition of peptidyl deformylase versus other metalloproteinases such as MMPs. Methods of preparation and use of the compounds are also disclosed.
    Type: Application
    Filed: May 22, 2006
    Publication date: July 3, 2008
    Inventors: Kathryn Rene Bracken, Simon Bushell, Karl Dean, Charles Francavilla, Rakesh K. Jain, Kwangho Lee, Mohindra Seepersaud, Lei Shu, Arathi Sundaram, Zhengyu Yuan
  • Patent number: 7381813
    Abstract: Mutants of steroid receptor ligand binding domains and synthetic ligands which have specific binding affinities for these receptors are provided. The use of these LBD-ligand combinations for construction of selective “molecular gene switches” is disclosed. Methods of regulating gene function using these switches are provided.
    Type: Grant
    Filed: May 31, 2002
    Date of Patent: June 3, 2008
    Assignee: Novartis AG
    Inventors: Kathryn Rene Bracken, Joseph Ernest de los Angeles, Ying Huang, Michael Joseph Kadan, Gary Michael Ksander, Dennis Bryan Zerby
  • Publication number: 20030143559
    Abstract: Mutants of steroid receptor ligand binding domains and synthetic ligands which have specific binding affinities for these receptors are provided. The use of these LBD-ligand combinations for construction of selective “molecular gene switches” is disclosed. Methods of regulating gene function using these switches are provided.
    Type: Application
    Filed: May 31, 2002
    Publication date: July 31, 2003
    Inventors: Kathryn Rene Bracken, Joseph Ernest de los Angeles, Ying Huang, Michael Joseph Kadan, Gary Michael Ksander, Dennis Bryan Zerby